These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26876066)

  • 1. The effect of hemodynamically-guided hypotensive therapy in one-year observation: Randomized, prospective and controlled trial (FINEPATH study).
    Krzesiński P; Gielerak G; Stańczyk A; Piotrowicz K; Uziębło-Życzkowska B; Banak M; Kurpaska M; Michalczyk Ł; Jurek A; Wolszczak K; Galas A; Wójcik A; Skrobowski A
    Cardiol J; 2016; 23(2):132-40. PubMed ID: 26876066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who benefits more from hemodynamically guided hypotensive therapy? The experience from two randomized, prospective and controlled trials.
    Krzesiński P; Gielerak G; Stańczyk A; Piotrowicz K; Skrobowski A
    Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):21-9. PubMed ID: 26634615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of impedance cardiography in optimisation of antihypertensive treatment in patients with metabolic syndrome: a randomised prospective clinical trial.
    Krzesiński P; Gielerak G; Kowal J; Piotrowicz K
    Kardiol Pol; 2012; 70(6):599-607. PubMed ID: 22718380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.
    Ayala DE; Hermida RC; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):340-52. PubMed ID: 23077973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.
    Hermida RC; Ayala DE; Fernández JR; Mojón A
    Chronobiol Int; 2013 Mar; 30(1-2):68-86. PubMed ID: 23181592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial.
    Staessen JA; Den Hond E; Celis H; Fagard R; Keary L; Vandenhoven G; O'Brien ET;
    JAMA; 2004 Feb; 291(8):955-64. PubMed ID: 14982911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in blood pressure control with impedance cardiography-guided pharmacologic decision making.
    Sharman DL; Gomes CP; Rutherford JP
    Congest Heart Fail; 2004; 10(1):54-8. PubMed ID: 14872160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.
    Georgianos PI; Agarwal R
    Am J Kidney Dis; 2015 Aug; 66(2):305-12. PubMed ID: 25818679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy.
    Ibrahim MM; el-Boghdadly B; Zaghloul SS
    J Hum Hypertens; 1996 Jul; 10(7):489-94. PubMed ID: 8880565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guiding Hypertension Management Using Central Blood Pressure: Effect of Medication Withdrawal on Left Ventricular Function.
    Kosmala W; Marwick TH; Stanton T; Abhayaratna WP; Stowasser M; Sharman JE
    Am J Hypertens; 2016 Mar; 29(3):319-25. PubMed ID: 26152757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension.
    Fadl Elmula FE; Hoffmann P; Larstorp AC; Fossum E; Brekke M; Kjeldsen SE; Gjønnæss E; Hjørnholm U; Kjaer VN; Rostrup M; Os I; Stenehjem A; Høieggen A
    Hypertension; 2014 May; 63(5):991-9. PubMed ID: 24591332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials.
    Ferrario CM; Flack JM; Strobeck JE; Smits G; Peters C
    Ther Adv Cardiovasc Dis; 2010 Feb; 4(1):5-16. PubMed ID: 20042450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial.
    Lu Y; Wang L; Wang H; Gu J; Ma ZJ; Lian Z; Zhang Z; Krumholz H; Sun N
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34580169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal denervation in moderate treatment-resistant hypertension.
    Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
    J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study.
    Mallion JM; Genès N; Vaur L; Clerson P; Vaïsse B; Bobrie G; Chatellier G
    J Hum Hypertens; 2001 Dec; 15(12):841-8. PubMed ID: 11773986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.